医学部附属病院

長谷川 直

Tadashi Hasegawa

基本情報

所属
千葉大学 医学部附属病院緩和ケアセンター 特任講師
学位
医学博士(2019年3月 千葉大学)

J-GLOBAL ID
202201002398828287
researchmap会員ID
R000039252

論文

 52
  • Masumi Tachibana, Nobuhisa Kanahara, Yasunori Oda, Tadashi Hasegawa, Atsushi Kimura, Masaomi Iyo
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2023年12月8日  
    STUDY OBJECTIVES: Although novel hypnotics have recently emerged, there are currently no data comparing the clinical potency of benzodiazepine receptor agonists (BZRAs) and novel hypnotics, or the effectiveness of different methods of switching between them. This study examined how novel hypnotics might help reduce BZRA use in real-world practice. METHODS: 289 patients with psychiatric disorders who took BZRAs for over 1 year before switching to either of two dual-orexin receptor antagonists (DORAs) (suvorexant (SUV) or lemborexant (LEM)) or a melatonin receptor agonist (ramelteon (RMT)) were enrolled. We collected data on BZRAs at baseline and 3 months after commencement of SUV/LEM/RMT. RESULTS: Significant reductions in BZRAs were observed for all three agents: -4.10, -2.80 and -1.65 mg in diazepam-equivalent dose in the SUV, LEM and RMT groups, respectively. Dose reduction was significantly greater in the DORA than the RMT group (F=15.053, P<0.001). Within the DORA group, dose reduction was significantly greater in patients taking SUV than those taking LEM (F=4.337, P=0.043). The switching success rate did not differ among the switching methods for any of the hypnotics. CONCLUSIONS: The reduction rate of BZRAs achieved by the switch fell into their equivalent-potency range estimated from clinical trials. The results suggest that DORAs can replace approximately one tablet of a BZRA. The difference in dose reduction between DORAs and RMT reflected the greater sleeping potency of the DORAs, whereas that between SUV and LEM might have reflected patient backgrounds: patients taking LEM may have been more strongly dependent on BZRAs.
  • 御園 覚夫, 島田 侑佳, 須川 裕之, 大木 望, 廣瀬 祐紀, 小田 靖典, 木村 敦史, 長谷川 直, 伊豫 雅臣
    精神神経学雑誌 125(1) 85-85 2023年1月  
  • 池水 結輝, 大木 望, 柴田 真太郎, 早津 龍之介, 小田 靖典, 木村 敦史, 長谷川 直, 伊豫 雅臣
    千葉医学雑誌 98(4) 107-107 2022年8月  
  • Tadashi Hasegawa, Tomomi Seo, Yoko Kubota, Tomoko Sudo, Kumi Yokota, Nao Miyazaki, Akira Muranaka, Shigeki Hirano, Atsushi Yamauchi, Kengo Nagashima, Masaomi Iyo, Ikuko Sakai
    Asian journal of psychiatry 67 102918-102918 2022年1月  
    Although many screening tools for delirium are available, delirium is still occasionally overlooked or misdiagnosed. One of the reasons for this is the lack of brief screening tools that do not require specialized training to use. The 4 'A's test (the 4AT) is a validated screening tool for delirium that can be administered in a very short time without specialized training. Herein, we evaluated the reliability and validity of the Japanese version of the 4AT (the 4AT-J). A total of 150 patients aged ≥ 65 years were enrolled. Their demographics and clinical characteristics were obtained within 24 hr of their hospitalization. On each patient's high-risk day of developing delirium, the 4AT-J was administered by a nurse, and the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-Ⅴ) and the Japanese version of Delirium Rating Scale-Revised-98 (DRS-98-J) were administered by a psychiatrist. Our analyses revealed that when a cut-off score of 4, the 4AT-J showed high sensitivity and specificity. The Cronbach's α-coefficient was similar to that of the original version. A receiver operating curve analysis showed sufficient power of the 4AT-J to discriminate delirium. The 4AT-J showed adequate reliability and validity for delirium screening in elderly patients.
  • Tetsuya Yamamoto, Kenichi Sakurai, Masahiro Watanabe, Ikki Sakuma, Nobuhisa Kanahara, Akihiro Shiina, Tadashi Hasegawa, Hiroyuki Watanabe, Masaomi Iyo, Ryoichi Ishibashi
    Diabetes therapy : research, treatment and education of diabetes and related disorders 12(9) 2611-2624 2021年9月  
    INTRODUCTION: Poor medication adherence and disordered eating are major self-care problems in patients with type 2 diabetes that worsen glycemic control and increase the risk of developing severe diabetes complications. Affective temperament, which remains mostly unchanged throughout life, is speculated to predict poor treatment response and high comorbidity. The aim of this study was to explore the link between affective temperament and poor glycemic control due to insufficient self-care. METHODS: This single-center case-control study involved 77 outpatients divided into the 'poor glycemic control' group (n = 52) and the 'better glycemic control' group (n = 25) based on their mean glycated hemoglobin (HbA1c) levels over the past 12 months. All participants underwent one-on-one interviews during which they completed the following psychometric questionnaires: (1) the Mini-International Neuropsychiatric Interview 5.0.0; (2) the Temperament Evaluation of Memphis, Pisa, and San Diego Auto-questionnaire; (3) a researcher-designed single question for assessing subclinical stress-induced overeating; and (4) the Morisky Medication Adherence Scale. The difference between two continuous independent variables was determined using Student's t test. Discrete variables were compared using the Chi-square (χ2) or Fisher's exact test. Multiple testing corrections were performed using the false discovery rate. RESULTS: Those outpatients in the poor glycemic control group exhibited significantly more stress-induced overeating (χ2 = 1.14, q statistic = 0.040) and poor medication adherence (t = 3.70, q = 0.034) than those in the better glycemic control group. However, there were no significant differences between the two groups in terms of affective temperaments, clinical eating disorders, or diabetes-specific distress. Patients with stress-induced overeating (t = - 2.99, p = 0.004) and poor medication adherence (t = - 4.34, p = 0.000) exhibited significantly higher scores for cyclothymic temperament than their counterparts. CONCLUSION: Cyclothymic temperament is significantly associated with disordered eating and/or poor medication adherence in patients with type 2 diabetes and is possibly linked to poor glycemic control.

MISC

 22

書籍等出版物

 5